Illumina introduced TruPath long‑read genome capabilities at the AGBT meeting, positioning the product as a competitor to PacBio’s native long reads and to other high‑throughput platforms in clinical sequencing. TruPath will initially be offered for research use only, with growing clinical interest anticipated. Company coverage at AGBT emphasised TruPath’s potential to expand Illumina’s clinical sequencing footprint, though adoption timelines and regulatory use remain to be clarified. Illumina framed TruPath as part of an expanded sequencing product suite intended to address long‑read applications in genomics and translational research.